The U.S. Food and Drug Administration just approved the first new antibiotic to treat urinary tract infections in nearly three decades ... UTIs caused by bacteria including E. coli, Klebsiella ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of oral antibiotics ... coli, Klebsiella pneumoniae, Citrobacter freundii ...

A new antibiotic ... Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis. More than half of all women will contract this kind of UTI in ...

GSK said the U.S. Food and Drug Administration approved its Blujepa oral antibiotic ... be used against urinary tract infections caused by the microorganisms Escherichia coli, Klebsiella ...

TUESDAY, March 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult ...

GSK’s oral antibiotic ... coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis. More than half of women are affected by UTIs, common ...

GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract infections ... like Escherichia coli, Klebsiella pneumoniae, Citrobacter ...

The U.S. Food and Drug Administration just approved the first new antibiotic to treat urinary tract infections in nearly ... by bacteria including E. coli, Klebsiella pneumoniae, Citrobacter ...